OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DMGP52

Dr Miele Cosmed Group SA

Personal ProductsVerified

Dr Miele Cosmed Group SA maintains a conservative capital structure with a debt-to-equity ratio of 0.23, indicating limited leverage relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.97, suggesting that current liabilities slightly exceed current assets. Free cash flow of 6.89 million PLN reflects modest cash generation after capital expenditures of -26.13 million PLN. Profitability metrics show a return on equity of 7.29% and a return on assets of 4.62%, which are below the industry median for personal products firms. The operating margin of 6.06% (30.54 million PLN operating income on 504.21 million PLN revenue) indicates moderate efficiency in converting revenue to operating profit. The company's revenue is concentrated in domestic and regional markets, with disclosed operations in Central and Eastern Europe, including Germany and the Russian Federation. No segment-specific revenue breakdown is available, but the geographic exposure suggests potential vulnerability to regional economic shifts. Growth trajectory is modest, with no specific revenue growth rate provided in the latest financials. The company's capital expenditures of -26.13 million PLN suggest a focus on cost management rather than expansion. Risk factors include a medium liquidity risk due to the current ratio of 0.97 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. Recent events include the company's rebranding from Global Cosmed SA to Dr Miele Cosmed Group SA, reflecting a strategic shift in branding and positioning.

30-day price · DMGP-0.46 (-17.0%)
Low$2.11High$2.85Close$2.24As of15 May, 00:00 UTC
Profile
CompanyDr Miele Cosmed Group SA
TickerDMGP.WA
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Products
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Dr Miele Cosmed Group SA maintains a conservative capital structure with a debt-to-equity ratio of 0.23, indicating limited leverage relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.97, suggesting that current liabilities slightly exceed current assets. Free cash flow of 6.89 million PLN reflects modest cash generation after capital expenditures of -26.13 million PLN. Profitability metrics show a return on equity of 7.29% and a return on assets of 4.62%, which are below the industry median for personal products firms. The operating margin of 6.06% (30.54 million PLN operating income on 504.21 million PLN revenue) indicates moderate efficiency in converting revenue to operating profit. The company's revenue is concentrated in domestic and regional markets, with disclosed operations in Central and Eastern Europe, including Germany and the Russian Federation. No segment-specific revenue breakdown is available, but the geographic exposure suggests potential vulnerability to regional economic shifts. Growth trajectory is modest, with no specific revenue growth rate provided in the latest financials. The company's capital expenditures of -26.13 million PLN suggest a focus on cost management rather than expansion. Risk factors include a medium liquidity risk due to the current ratio of 0.97 and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. Recent events include the company's rebranding from Global Cosmed SA to Dr Miele Cosmed Group SA, reflecting a strategic shift in branding and positioning.
Key takeaways
  • Dr Miele Cosmed Group SA operates with a low debt-to-equity ratio, indicating a conservative capital structure.
  • The company's return on equity and return on assets are below the industry median, suggesting room for improvement in profitability.
  • Revenue is concentrated in regional markets, with no disclosed segment-specific breakdown.
  • Free cash flow is modest, and capital expenditures are negative, indicating a focus on cost control.
  • Liquidity risk is medium, and dilution risk is low.
  • --
  • **RATIONALES**:
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPLN
Revenue$504.2M
Gross profit$212.2M
Operating income$30.5M
Net income$19.7M
R&D
SG&A
D&A
SBC
Operating cash flow$39.1M
CapEx-$26.1M
Free cash flow$6.9M
Total assets$425.8M
Total liabilities$155.6M
Total equity$270.3M
Cash & equivalents
Long-term debt$63.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$270.3M
Net cash-$63.2M
Current ratio1.0
Debt/Equity0.2
ROA4.6%
ROE7.3%
Cash conversion2.0%
CapEx/Revenue-5.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Personal Products · cohort 225 companies
MetricDMGPActivity
Op margin6.1%16.2% medp25 16.2% · p75 16.2%bottom quartile
Net margin3.9%10.5% medp25 10.5% · p75 10.5%bottom quartile
Gross margin42.1%60.1% medp25 60.1% · p75 60.1%bottom quartile
R&D / revenue1.8% medp25 1.8% · p75 1.8%
CapEx / revenue-5.2%-2.3% medp25 -4.4% · p75 -1.1%bottom quartile
Debt / equity23.0%12724.1% medp25 12724.1% · p75 12724.1%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 04:47 UTC#946cef47
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 04:49 UTCJob: 1320573d